DMS : the Finalization of the sale of the shareholding in Alpha MOS for an amount of 6.5 M…

Diagnostic Medical Systems Group (Euronext Paris – FR0012202497 – DGM) has finalised the sale of all of the 14 379 830 shares held in the share capital of the company Alpha MOS (Euronext Paris – FR0000062804 – ALM), representing 42,94% of the capital and 49,98% of the voting rights, to funds managed by the management company of Jolt Capital and investment company Ambrosia Investments.

Download the free guide
Boost your gains

This assignment has been executed at a price of 0.45 € per share, representing a total amount of 6.5 M€.

Alpha MOS will be deconsolidated in the scope of the DMS Group as of June 30, 2017.

As a result of this transaction, Jean-Paul Ansel, President and ceo of DMS Group, has resigned the presidency of the Board of directors of Alpha MOS, as well as the post of the Director general of the company.

Jean-Paul Ansel, President and ceo of DMS Group, said :

“The sale of the stake in Alpha MOS, following a phase of restructuring and promising developments, will allow the MDS Group to refocus on its activities DMS Imaging, which were recorded, for several years now, growing steadily.

This assignment will also serve to strengthen the financial capacity of the group to accelerate the development of DMS Wellness, a division dedicated to the sector of the health and well-being, which will begin the marketing of the solution Celliss the 2nd half, and to accompany the rise in power of the products of lipofilling as well as the preclinical and clinical studies of the division DMS Biotech.”

Next appointment : publication of turnover for the 1st half of 2017 25 July 2017 after the closing of the regulated market of Euronext Paris.

About DMS Group

DMS Group is comprised of companies with high innovation potential. First of all focused on the medical imaging industry, it now extends to new horizons. By investing for the future and making the bet of research, DMS Group hopes to bring the solutions of tomorrow.

Specialized in high technology at the service of the diagnosis, medical, DMS Imaging, positioning itself today as the French leader in the development, design and manufacturing of imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.

DMS Wellness includes activities devoted to the sector of the health and well-being, addressing to the specialists of the physiotherapy, beauty, aesthetics and sport.

DMS Biotech accompanies the group’s development strategy in the field of biotechnology, and particularly technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of fat stem cells.

DMS Group is present on all continents through a network of more than 140 national distributors, subsidiaries and joint-venture. In 2016, DMS Group achieved a consolidated turnover of 37.4 Million euros. DMS Group is listed on the Euronext market in Paris (ISIN : FR0012202497 – mnémo : DGM).

More information on

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply